1-3 of 3
Pierre Vera, MD
Close
Sort by
Journal Articles

Molecular Profile and FDG-PET/CT Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B Cell Lymphoma

Anne-Ségolène Cottereau, MD, Hélène Lanic, MD, Michel Meignan, MD PhD, Pierre Vera, MD PhD, Hervé Tilly, MD PhD, Fabrice Jardin, MD PhD, Stéphanie Becker, MD PhD
Journal: Blood
Blood (2015) 126 (23): 1452.
https://doi.org/10.1182/blood.V126.23.1452.1452
Published: 2015
Journal Articles

Interim [18F]Fluorodeoxyglucose Positron Emission Tomography SUVmax Reduction Is Superior to Visual Analysis to Predict Early patient's Outcome In Diffuse Large B-Cell Lymphoma

Rene-Olivier Casasnovas, MD, Michel Meignan, MD, Alina Berriolo-Riedinger, MD, Stephane Bardet, MD, Anne Julian, MD, Catherine Thieblemont, MD, Pierre Vera, MD, Serge Bologna, MD, Josette Briere, MD, Jean-Philippe Jais, MD, Corinne Haoiun, MD, Bertrand Coiffier, MD, PhD, Franck Morschhauser, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 320.
https://doi.org/10.1182/blood.V116.21.320.320
Published: 2010
Journal Articles

Patient-Specific Three Dimensional (3D) Dosimetry for 90 Y Ibritumomab Tiutexan (Zevalin®) in Patients with Follicular Lymphoma.

Karine Assié, PhD, Arnaud Dieudonné, PhD, Isabelle Gardin, PhD, Irène Buvat, PhD, Hervé Tilly, MD, Pierre Vera, MD
Journal: Blood
Blood (2005) 106 (11): 4780.
https://doi.org/10.1182/blood.V106.11.4780.4780
Published: 2005